|
See related Sprycel film-coated tab information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Dasatinib |
|
Indications |
Treatment of adults w/ chronic, accelerated, myeloid or lymphoid blast phase chronic myeloid leukemia (CML) w/ resistance or intolerance to prior therapy including imatinib; adults w/ Philadelphia chromosome +ve acute lymphoblastic leukemia w/ resistance or intolerance to prior therapy.
Click to view Sprycel detailed prescribing infomation |
|
Dosage |
Chronic phase CML 100 mg once daily. Accelerated phase, myeloid or lymphoid blast CML 140 mg once daily. Administration w/ a CYP3A4 inhibitor may reduce dose to 20 mg daily.
Click to view Sprycel detailed prescribing infomation |
|
Overdosage |
View Sprycel overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not break/crush/cut.). |
|
Special Precautions |
Myelosuppression, perform complete blood count wkly for the 1st 2 mth & mthly thereafter or as clinically indicated. Caution in patients taking anticoagulants or antiplatelets. Patients who develop symptoms suggestive of pleural effusion eg dyspnea or dry cough should be eva luated by chest x-ray. Patients who have or may develop QTc prolongation. Correct hypokalemia or hypomagnesemia prior to administration. Hepatic impairment. Pregnancy & lactation. Elderly. Childn <18 yr.
Click to view Sprycel detailed prescribing infomation |
|
Adverse Drug Reactions |
Fluid retention, diarrhea, headache, skin rash, nausea, hemorrhage, fatigue, dyspnea; pleural effusion, pyrexia, pneumonia, infection, febrile neutropenia, GI bleeding, dyspnea, sepsis, CHF, pericardial effusion.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inhibitors (eg ketoconazole, itraconazole, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, voriconazole); CYP3A4 inducers (eg dexamethasone, phenytoin, carbamazepine, rifampicin, rifabutin, phenobarb); CYP3A4 substrates [eg alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus or ergot alkaloids (ergotamine, dihydroergotamine)]; St. John's wort, antacids, H2-blockers/proton-pump inhibitors. Grapefruit juice.
View more drug interactions with Sprycel |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Sprycel detailed prescribing infomation |
|
Storage |
View Sprycel storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Sprycel description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Sprycel mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
